ARS Pharma posts Q3 2026 results, highlights neffy share gains and CSU trial timeline

ARS Pharmaceuticals reported third-quarter 2026 financial results and business updates on November 5, 2026. Total third-quarter revenue was $37.7 million, including $33.4 million in U.S. net product revenue for neffy.¹

On the pipeline side, the company said its needle-free epinephrine candidate ARS-2 is being tested in a Phase 2b study evaluating 0.5 mg and 1.0 mg doses for on-demand treatment of breakthrough flares in patients with chronic spontaneous urticaria (CSU)¹. The company noted that an estimated two million Americans live with CSU, and no FDA-approved therapy is indicated to stop an acute flare in progress.¹ ARS Pharma said interim results from the Phase 2b study are anticipated in the first quarter of 2027, with full results following later that year, data the company said would shape plans for a possible Phase 3 program.¹

On the commercial side, neffy's total U.S. market share reached 5% in the third quarter of 2026, up from 4% in the third quarter of 2025.¹ The company said share in field-targeted accounts, which it estimates make up about 44% of the total market opportunity, rose to approximately 9% from 6% a year earlier, compared with 2% share in non-targeted accounts in the third quarter of 2026.¹

Leadership changes included the appointments of Randall Kaye as Chief Medical Officer and John Slebir as Chief Legal Officer, part of a strengthened leadership team disclosed alongside the quarterly results.¹

On cash position, as of September 30, 2026, ARS had cash, cash equivalents and short-term investments of $138.4 million.¹ The company said it continues to expect to reach cash flow breakeven by the end of 2027 based on its current expense plan.¹